Skip to content
ModernDoc
Get the app

Menopausal Hormone Therapy

Menopause — Living Evidence Monitor

Data last updated 2 studies cited

How this page is produced

Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This is an AI-assisted evidence summary, not a clinician endorsement and not medical advice. Read how we build and check these pages.

KEY FINDINGS

Clinically meaningful worsening of sexual function at 6 months after RRSO vs ISDO
OR 2.00
95% CI: 1.20-3.35
Source [1] · DOI ·
Clinically meaningful worsening of sexual function at 12 months after RRSO vs ISDO
OR 1.69
95% CI: 1.09-2.63
Source [1] · DOI ·
RRSO patients with clinically meaningful worsening of sexual function at 6 months
33.1%
Source [1] · DOI ·
ISDO patients with clinically meaningful worsening of sexual function at 6 months
16.8%
Source [1] · DOI ·
Sexual function and menopausal symptoms in RRSO patients who used hormone replacement therapy
no significant worsening
Source [1] · DOI ·
Overall hormone therapy and Parkinson's disease risk
RR 1.08
95% CI: 0.94-1.23
Source [2] · DOI ·
Combined estrogen-progestin therapy and Parkinson's disease risk
RR 1.40
95% CI: 1.07-1.82
Source [2] · DOI ·
Estrogen-only therapy and Parkinson's disease risk
RR 1.01
95% CI: 0.81-1.27
Source [2] · DOI ·
Combined therapy in multilevel analysis
RR 1.33
95% CI: 1.00-1.77
Source [2] · DOI ·
Estrogen-only therapy in multilevel analysis
RR 1.03
95% CI: 0.83-1.27
Source [2] · DOI ·
Interaction test comparing Parkinson's disease risk estimates between hormone-therapy formulations
p = 0.12
Source [2] · DOI ·

SOURCES

  1. [1]Lu, Karen H et al.. Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial.. JAMA network open. 2026. DOI (opens in new tab)
  2. [2]Macedo, Victor Fellipe Bispo et al.. Differential effects of hormone therapy formulations on Parkinson's disease risk: a systematic review and meta-analysis.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2026. DOI (opens in new tab)

Get an email when this evidence changes

ModernDoc will email you when a validated finding on this page is added or corrected — nothing else, no marketing. There is no fixed schedule: if the evidence doesn't change, we don't email.

We'll first send one confirmation email — you're not subscribed until you click it. Subscribing signals an interest in Menopause; we treat that as sensitive: we store only your email address and this topic, never linked to any health record, and never shared or sold. Every email includes a one-click unsubscribe link. Sent by ModernDoc (moderndoc.co).

See a problem with the Menopausal Hormone Therapy evidence?

Send a source correction or freshness concern. We cannot provide personal medical advice through this site.

Report a correction